Junik Junior

Beclometasone Dipropionate, the active ingredient in Junik Junior, is a corticosteroid presented as an inhalation spray for inhalation use. It is indicated for the long‑term management of asthma and chronic obstructive pulmonary disease in patients who require anti‑inflammatory therapy. GNH USA supplies Junik Junior as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Beclometasone Dipropionate is an inhaled corticosteroid that targets airway inflammation in respiratory disease. - Asthma: reduces airway inflammation and helps prevent symptoms and exacerbations. - Chronic obstructive pulmonary disease (COPD): decreases inflammation to improve breathing stability and reduce flare‑ups. - Exercise‑induced bronchoconstriction: helps control airway narrowing triggered by physical activity.

Adverse reactions may occur with inhaled beclometasone therapy.

Common Side Effects: - Hoarseness or voice change. - Oral candidiasis (thrush). - Cough or throat irritation. - Headache. - Sore throat. - Nasal congestion.

Serious or Rare Side Effects: - Adrenal suppression. - Pneumonia. - Cataracts or glaucoma. - Severe allergic reaction (anaphylaxis). - Growth suppression in children. - Osteoporosis with long‑term high‑dose use.

Before using Junik Junior, consider the following safety measures. - Monitor lung function: regular assessment of asthma or COPD control. - Use a spacer device: helps reduce oropharyngeal deposition. - Avoid abrupt discontinuation: taper under medical supervision to prevent rebound inflammation. - Report infections: inform healthcare provider if respiratory infections develop. - Pregnancy and lactation: safety not established; discuss risks with a physician. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Beclometasone Dipropionate may interact with other medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase systemic corticosteroid exposure. - Concomitant use with other inhaled corticosteroids can raise risk of systemic effects.

Moderate Interactions (Monitor Closely): - Beta‑agonists may increase tremor or palpitations. - Diuretics may enhance risk of hypokalemia. - Moderate CYP3A4 inhibitors (e.g., fluconazole) may modestly raise drug levels.